Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 5/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 5/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 7/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136940 | 0.92 | KCNQ3 (0.34) | KCNQ3KCNQ2KCNE1KCNQ1CNR1 | |
| SCHEMBL4131694 | 0.92 | KCNQ3 (0.36) | KCNQ3KCNQ2KCNE1KCNQ1CNR1 | |
| SCHEMBL4125531 | 0.90 | CNR1 (0.40) | KCNQ3KCNQ2CNR1P2RX7CNR2 | |
| SCHEMBL4118494 | 0.87 | SMN1; SMN2 (0.33) | KCNQ3KCNQ2KCNE1KCNQ1P2RX7 | |
| SCHEMBL4127374 | 0.86 | SCN9A (0.37) | KCNQ3KCNQ2CNR1P2RX7NPC1 | |
| SCHEMBL4125753 | 0.86 | CNR1 (0.34) | KCNQ3KCNQ2KCNE1KCNQ1CNR1 | |
| SCHEMBL4130354 | 0.86 | RXRA (0.32) | KCNQ3KCNQ2KCNE1KCNQ1CNR1 | |
| SCHEMBL4123908 | 0.85 | SMN1; SMN2 (0.37) | KCNQ3KCNQ2P2RX7NPC1RAB9A | |
| SCHEMBL4135601 | 0.84 | SMN1; SMN2 (0.34) | KCNQ3KCNQ2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4130715 | 0.84 | KCNQ3 (0.32) | KCNQ3KCNQ2KCNE1KCNQ1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | KCNQ3 4287/4885KCNQ2 3933/4885KCNE1 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.